ARS Pharmaceuticals (Nectin-4 Antibody) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

ARS Pharmaceuticals (Nectin-4 Antibody) General Information

Description

Antibody-drug tumor-associated antigen overexpressed in a variety of large tumor indications and has been used as a target in ADC development previously.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • San Diego, CA
  • United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • San Diego, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ARS Pharmaceuticals (Nectin-4 Antibody) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ARS Pharmaceuticals (Nectin-4 Antibody)‘s full profile, request access.

Request a free trial

ARS Pharmaceuticals (Nectin-4 Antibody) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ARS Pharmaceuticals (Nectin-4 Antibody)‘s full profile, request access.

Request a free trial

ARS Pharmaceuticals (Nectin-4 Antibody) FAQs

  • Where is ARS Pharmaceuticals (Nectin-4 Antibody) headquartered?

    ARS Pharmaceuticals (Nectin-4 Antibody) is headquartered in San Diego, CA.

  • What industry is ARS Pharmaceuticals (Nectin-4 Antibody) in?

    ARS Pharmaceuticals (Nectin-4 Antibody)’s primary industry is Buildings and Property.

  • Is ARS Pharmaceuticals (Nectin-4 Antibody) a private or public company?

    ARS Pharmaceuticals (Nectin-4 Antibody) is a Private company.

  • What is ARS Pharmaceuticals (Nectin-4 Antibody)’s current revenue?

    The current revenue for ARS Pharmaceuticals (Nectin-4 Antibody) is .

  • Who are ARS Pharmaceuticals (Nectin-4 Antibody)’s investors?

    ARS Pharmaceuticals has invested in ARS Pharmaceuticals (Nectin-4 Antibody).

  • When was ARS Pharmaceuticals (Nectin-4 Antibody) acquired?

    ARS Pharmaceuticals (Nectin-4 Antibody) was acquired on 17-Apr-2023.

  • Who acquired ARS Pharmaceuticals (Nectin-4 Antibody)?

    ARS Pharmaceuticals (Nectin-4 Antibody) was acquired by Araris.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process